Opko Health OPK Pharmaceutical — D&A

Similar metrics at other companies

AMP

AMPHPharmaceutical Products — D&A

$14.35M+5.4%

PFEBiopharma — D&A

$348M+5.1%

ATRPharma — D&A

$35.64M+14.4%

CAHPharmaceutical and Specialty Solutions — D&A

$70M+59.1%

CVSPharmacy & Consumer Wellness — D&A

$406M+5.7%

ASSTMedical Device — D&A

$32K—

Questions, answered.

What is Opko Health's pharmaceutical — D&A?

Opko Health (OPK) reported pharmaceutical — D&A of $18.26M in Q1 2026.

How has Opko Health's pharmaceutical — D&A changed year-over-year?

Opko Health's pharmaceutical — D&A increased by 2.7% year-over-year, from $17.79M to $18.26M.

What is the long-term trend for Opko Health's pharmaceutical — D&A?

Over 4 years (2021 to 2025), Opko Health's pharmaceutical — D&A has grown at a 28.6% compound annual growth rate (CAGR), from $26.43M to $72.26M.

What does pharmaceutical — D&A mean?

This metric represents the total non-cash expense allocated to the pharmaceutical segment for the systematic reduction in the value of tangible and intangible assets over their useful lives. It reflects the capital intensity of the pharmaceutical business, including manufacturing facilities and acquired intellectual property. Monitoring this helps investors understand the segment's ongoing investment in infrastructure and technology.